Efficacy and Safety of Thalidomide Combined with Cyclosporine in the Treatment of Corticosteroid-resistant or Relapsed ITP: a Single Arm Clinical Study

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-17012860

Enrollment

Unknown

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Thrombocytopenia

Interventions

Case series:Thalidomide + Cyclosporine

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 15 to 65 Years; 2. Corticosteroid-resistant,Primary or second-line medications were effective, but they were not effective after reduction or discontinuation, or Relapsed ITP; PLT>30×10^9/L; 3. Completed the examination of hepatitis virus, T cell subset, ANA, platelet associated immunoglobulin.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation; 2. Thalidomide allergy; 3. Drug-induced thrombocytopenia; 4. virus-induced thrombocytopenia, such as HIV, hepatitis B virus, or hepatitis C virus; 5. Active systemic infection; 6. Complicated by tumors or other autoimmune diseases.

Design outcomes

Primary

Measure	Time frame
Platelet count;	—

Secondary

Measure	Time frame
Tregs;Bregs;	—

Countries

China

Contacts

Public ContactZhigang Yang

Affiliated Hospital of Guangdong Medical University

yangzg@gdmu.edu.cn+86 13560512702

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026